A Study Evaluating the Safety of Escalating Doses of DLYE5953A in Patients With Refractory Solid Tumors

NCT02092792 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: DLYE5953A
DRUG: DLYE5953A

Sponsor

Genentech, Inc.